Pliant Therapeutics, Inc. (PLRX)
Stock Price:
$26.37 USD
-0.23 (-0.85%)
Updated Jul 9, 2020 9:59 AM EDT - Market open
Key Info
| Market Cap |
647.95M |
| Revenue (ttm) |
85.99M |
| Net Income (ttm) |
-631,000 |
| Shares Out |
34.20M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$26.37 |
| Previous Close |
$26.59 |
| Change ($) |
-0.23 |
| Change (%) |
-0.85% |
| Day's Open |
26.56 |
| Day's Range |
25.90 - 26.56 |
| Day's Volume |
4,628 |
| 52-Week Range |
21.05 - 35.63 |
More Stats
| Market Cap |
647.95M |
| Enterprise Value |
545.18M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.20M |
| Float |
1.02M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-2.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
112,250 |
| Short Ratio |
0.13 |
| Short % of Float |
0.45% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.54 |
| PB Ratio |
5.82 |
| Revenue |
85.99M |
| Operating Income |
-1.23M |
| Net Income |
-631,000 |
| Free Cash Flow |
-3.71M |
| Net Cash |
102.77M |
| Net Cash / Share |
4.18 |
| Gross Margin |
66.35% |
| Operating Margin |
-1.43% |
| Profit Margin |
-12.00% |
| FCF Margin |
-4.32% |
| ROA |
12.56% |
| ROE |
22.15% |
| ROIC |
-4.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$43.33*
(64.35% upside)
Low
40.0
Current: 26.37
High
50.0
Target: 43.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 57.05 | - |
| Gross Profit | 57.05 | - |
| Operating Income | -1.23 | -30.92 |
| Net Income | -0.63 | -30.28 |
| Shares Outstanding | 1.62 | 1.17 |
| Earnings Per Share | -4.22 | -30.16 |
| Operating Cash Flow | -2.75 | -28.33 |
| Capital Expenditures | -0.96 | -2.32 |
| Free Cash Flow | -3.71 | -30.65 |
| Cash & Equivalents | 103 | 60.95 |
| Net Cash / Debt | 103 | 60.95 |
| Assets | 119 | 66.53 |
| Liabilities | 9.08 | 5.90 |
| Book Value | -76.30 | -71.47 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pliant Therapeutics, Inc. |
| Country |
United States |
| Employees |
62 |
| CEO |
Bernard Coulie |
Stock Information
| Ticker Symbol |
PLRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PLRX |
| IPO Date |
June 3, 2020 |
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.